Congenital malformations surveillance: two American systems. Int J Epidemiol 1981 Sep;10(3):247-52
Date
09/01/1981Pubmed ID
7287285DOI
10.1093/ije/10.3.247Scopus ID
2-s2.0-0019812886 (requires institutional sign-in at Scopus site) 197 CitationsAbstract
As part of its epidemiologic studies of congenital malformations, the Centers for Disease Control (CDC) conducts two birth defects surveillance systems in the United States. The Metropolitan Atlanta Congenital Defects Programme (MACDP) is an intensive surveillance system using several methods to identify infants born with birth defects in the Atlanta area. The Birth Defects Monitoring Programme (BDMP) is a nationwide surveillance system that monitors 1 million births per year, about a third of all births in the U.S. It relies on diagnoses from newborn discharge summaries to ascertain affected infants. The systems were originally designed to detect potential 'epidemics' of birth defects that could occur following the widespread dissemination of new teratogens similar to thalidomide. In addition to monitoring, they have also proved to be useful resources for a variety of studies of the epidemiology of birth defects.
Author List
Edmonds LD, Layde PM, James LM, Flynt JW, Erickson JD, Oakley GP JrAuthor
Peter M. Layde MS, MD Emeritus Professor in the Emergency Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Abnormalities, Drug-InducedCongenital Abnormalities
Data Collection
Humans
Methods
Thalidomide
United States
